Drug Trial Radar · NCT03068481
Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Apr 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Feb 20, 2017
Primary completion
Aug 13, 2018
Study completion Aug 13, 2018
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 74 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study in healthy adult males is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594. The purpose of this study in patients with Parkinson's disease is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594. The exploratory efficacy of KDT-3594 will also be investigated.
Conditions
- Parkinson Disease
Interventions
KDT-3594Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse eventsTime frame: Up to 15 days after last administration
- Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: CmaxTime frame: Up to 336 hours after last administration
- Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: AUCTime frame: Up to 336 hours after last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Kyushu and Other Regions, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.